Abcuro key facts
as of Oct 2026- Developer of immunomodulatory therapeutics designed for treating both autoimmunity and cancer.
- Abcuro is valued at approximately $700.0M as of Oct 2026, set at its later-stage round, Feb 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $407.3M across 5 recorded rounds; the latest was Later Stage VC (Series C) ($200.0M) in Feb 2025.
- Notable investors include RA Capital Management, New Enterprise Associates, BlackRock, Foresite Capital, Samsara BioCapital — 20 tracked in total.
- Abcuro has filed 6 Form Ds with the SEC since 2016, most recently Feb 2025 ($80.0M sold to 21 investors).
- Status: Privately Held (backing).
Valued at $700.0M at its later-stage round, Feb 2025. Nothing has traded since.
- ·The complete investor list: 20 names
- ·Watch Abcuro: the Monday email on marks, rounds and moves
Abcuro funding rounds
5 roundsWho backs Abcuro
20+Abcuro valuation
Abcuro was valued at $700 million at its later-stage round in Feb 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Abcuro raised?
Abcuro has raised $407 million across 5 recorded rounds since 2016. The largest was an $8 million early-stage round in Nov 2018; the most recent was a $200 million Series C in Feb 2025.
Abcuro has filed 6 Form Ds with the SEC since 2016, most recently in Feb 2025 ($80 million sold to 21 investors).
Abcuro investors
20 investors are on record for Abcuro, including RA Capital Management, New Enterprise Associates, BlackRock and Foresite Capital. By type, the record holds 5 venture capital firms, 2 private equity firms and 1 asset manager. The Series C in Feb 2025 drew 13 investors.
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: Bluejay Therapeutics ($820 million), Candid Therapeutics ($657 million) and Kardigan ($646 million).
About Abcuro
Developer of immunomodulatory therapeutics designed for treating both autoimmunity and cancer. The company uses proprietary analysis of transcription data from human disease to identify new approaches to target key immune system compartments, enabling healthcare professionals to plan appropriate procedures for efficient treatments.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Newton, MA, United States
- Founded
- 2015
- Employees
- 55
- Website
- abcuro.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.